- Home
- Clinical Trials
Alopecia Areata Study Wellington M23
Alopecia Areata Study
Wellington
Help support research aimed at advancing treatments for yourself and others living with alopecia areata.
Please note that this study has now closed. However, we encourage you to pre-register your interest for future alopecia studies here.
Description
What to expect
Study details
Ages
12 to 63 years old
Duration
Variable
Compensation
Participants may be reimbursed for any reasonable travel, parking, and other expenses associated with study visits.
Eligibility Criteria
You may be eligible to take part if you
- Are aged 12 to 63 years of age
- Have been diagnosed with severe alopecia areata
- Have at least 50% hair loss
- Are in generally in good health
- Don’t have a diagnosis of other types of inflammatory scalp, eyebrow, or eyelash disorders, including but not limited to seborrheic dermatitis, scalp psoriasis, atopic dermatitis, and tinea capitis; or
- Have not received the following treatment within the last 4 weeks: Phototherapy, Tanning booth therapy, cryotherapy, laser therapy (e.g., excimer laser) used for alopecia areata on the scalp, intralesional corticosteroid or PRP injections, microneedling, or microtattooing.
Locations
Description
Alopecia areata is a common but often misunderstood condition that causes hair loss. It's an autoimmune disorder where the immune system mistakenly attacks hair follicles, leading to hair falling out in small, usually round patches on the scalp or other parts of the body. This can be distressing for those affected because it can happen suddenly and affect their appearance. While not physically harmful, it can have a significant impact on a person's self-esteem and quality of life.
Currently, there's no approved systemic treatment for people with severe hair loss (alopecia areata), and there's a significant need for more options for both teenagers and adults. An investigational medication has been developed, which could potentially help treat severe hair loss in both age groups. This investigational medication has been approved for various other conditions and is being studied for additional immune-related diseases, including alopecia areata.
What to expect
This clinical trial aims to determine how well two different doses of the investigational medication (a tablet taken by mouth once a day) works in treating the symptoms of severe hair loss in both adults and, in some places, teenagers. This clinical research is designed to find out if the investigational medication is effective, safe, and easy for people to tolerate when compared to a placebo (a dummy pill with no active ingredient).